Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials

Icotinib is the first generation of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) independently developed in China, which has been widely used in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer (NSCLC). The purpose of this study was to systematicall...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dailong, Yao, Ling, Xu, Lu, Li, Wanqiang, Che, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726281/
https://www.ncbi.nlm.nih.gov/pubmed/36482605
http://dx.doi.org/10.1097/MD.0000000000032164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726281/
https://www.ncbi.nlm.nih.gov/pubmed/36482605
http://dx.doi.org/10.1097/MD.0000000000032164

Ejemplares similares